Entrada Therapeutics Inc
NASDAQ:TRDA
Entrada Therapeutics Inc
Net Change in Cash
Entrada Therapeutics Inc
Net Change in Cash Peer Comparison
Competitive Net Change in Cash Analysis
Latest Figures & CAGR of Competitors
Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Entrada Therapeutics Inc
NASDAQ:TRDA
|
Net Change in Cash
$22.4m
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Net Change in Cash
$11.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
26%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Change in Cash
-$218m
|
CAGR 3-Years
67%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Change in Cash
-$21.9B
|
CAGR 3-Years
-140%
|
CAGR 5-Years
-56%
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Change in Cash
-$126.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Change in Cash
-$1.3B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Entrada Therapeutics Inc's Net Change in Cash?
Net Change in Cash
22.4m
USD
Based on the financial report for Dec 31, 2023, Entrada Therapeutics Inc's Net Change in Cash amounts to 22.4m USD.
What is Entrada Therapeutics Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 3Y
0%